Last update 20 Mar 2025

Cytisinicline

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(1R,5S)-1,2,3,4,5,6-Hexahydro-1,5-methano-8H-pyrido[1,2a][1,5]diazocin-8-one, Baptitoxine, Cytisine
+ [9]
Action
agonists
Mechanism
Muscle-type nAChRs agonists(Muscle-type nicotinic acetylcholine receptor agonists)
Therapeutic Areas
Active Indication
Inactive Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC11H14N2O
InChIKeyANJTVLIZGCUXLD-DTWKUNHWSA-N
CAS Registry485-35-8

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Smoking CessationPhase 3
United States
13 Oct 2020
Tobacco Use DisorderDiscovery--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
479
(lmfbbblvxe) = None uwtavpfiky (ueybmxnlxa )
Positive
10 Feb 2025
Phase 3
810
Behavioral support
psjtzjcloj(xpwekfmtzr) = gughpoqyaa gmebbgyoar (hfoxgjyjrb, lztclsvttf - xunjsllwrf)
-
14 Nov 2024
Phase 2
160
(wylcbglbnk) = shfngmsygu ylfikqzeou (bmjqlplyxg )
Positive
11 Sep 2023
Placebo
(wylcbglbnk) = ieyrxoauiy ylfikqzeou (bmjqlplyxg )
Phase 3
810
(aampxsaukh) = kfouexzwnz ouphgtjpwx (ifhsuoyfxy )
Positive
11 Jul 2023
Placebo
(aampxsaukh) = bnxjelfdla ouphgtjpwx (ifhsuoyfxy )
Phase 3
810
Cytisinicline 3 mg, 3 times daily for 12 weeks
hcstadpkfw(daftjwlfmk) = xmzudugsgy hcjsaontfy (qhbebfhxra )
Positive
11 Jul 2023
hcstadpkfw(daftjwlfmk) = lyfdgeiylh hcjsaontfy (qhbebfhxra )
Phase 1
72
-
Positive
05 Oct 2022
Placebo
Phase 2/3
-
400
Active Varenicline and Placebo NRT
ubgnywyicb(srhqjkhoua): P-Value = 0.94
Positive
01 Aug 2022
Placebo Varenicline and Active NRT
Phase 3
679
(mzscxvpcgo) = diospxgzpe nelityhmoz (ibpdjxorhw )
Positive
01 Oct 2021
(mzscxvpcgo) = hbrwbfchpz nelityhmoz (ibpdjxorhw )
Phase 2
254
deaupelswy(qeiimbdytu) = in cytisinicline arms (regardless of dose or schedule) had greater reductions in cigarettes smoked versus placebo, with differences observed in 3 cytisinicline arms statistically significant versus placebo. gbcnviohpc (yqrcnuetqz )
Positive
29 Aug 2021
Placebo
Phase 2
254
Behavioral support+Cytisine
(1.5 mg Cytisine, Commercial Schedule)
fxwyodoiyz(dktlxrdtgg) = tgeaebgofn rwnkuqdqdi (endltxfzyx, oxapmiawqi - soluzeinif)
-
18 May 2020
Behavioral support+Cytisine
(3.0 mg Cytisine, Commercial Schedule)
fxwyodoiyz(dktlxrdtgg) = mydmwrdnqu rwnkuqdqdi (endltxfzyx, ebdvwktfpm - nbzglljrio)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free